S PATENT AND TRADEMARK OFFICE

United States Patent and Trademark Office United States Patent and Trademark Office Adress: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/761,006

01/20/2004

Chong Jin Oon

U 014987-0

00140 LADAS & PARRY 26 WEST 61ST STREET NEW YORK, NY 10023

**CONFIRMATION NO. 1820 FORMALITIES LETTER** OC000000012326003\*

Date Mailed: 04/09/2004

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

Practitioner's Docket No. <u>U 014987-0</u>

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chong Jin OON, et al

Serial No.: 10/761,006

Group No.: 1645

Filed: January 20, 2004

Examiner:

For: MUTANT HUMAN HEPATITIS B VIRAL STRAIN AND USES THEREOF

Mail Stop Sequence Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

### SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

#### CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

CO TRAU

#### **MAILING**

×	deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.		
	37 C.F.R. 1.8(a)	37 C.F.R. 1.10*	

×	with sufficient postage as first class mail.		as "Express Mail Post Office to	Address"
		TRANSMISSION	Mailing Label No.	(mandatory)
	transmitted by facsimile to the Patent and Trad	emark Office. to (703	3) 872-9306	
		Sig	nature /	
Dat	te: _June 17, 2004	(typ	SLIFFORD J. MASS	ing)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Submission-Nucleotide and/or Amino Acid Sequence-page 1 of 6) 9-37

06/22/2004 MBLANCO 00000002 10761006

01 FC:1251

110.00 GP

## 1. [X] This replies to the Office Letter dated April 9, 2004

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

[x] A copy of the Office Letter is enclosed.

#### IDENTIFICATION OF PERSON MAKING STATEMENT

2.	I, <u>CLIFFORD J. MASS</u>	
	(type or print name of person signing below)	
	state the following:	

#### ITEMS BEING SUBMITTED

3. Submitted herewith is/are

(check each item as applicable)

- A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. 1.821(c) and 37 C.F.R. 1.822 and 1.823.
- B. [X] An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. 1.821(d).
- C. [X] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. 1.821(e) and 1.824.
- D. [] Please transfer to this application, in accordance with 37 C.F.R. 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

(Submission-Nucleotide and/or Amino Acid Sequence—page 2 of 6) 9-37

In re application of:		
	Serial No.:	Group No.:
	Filed:	Examiner:
	For:	
	Computer readable former e Identifier(s)" of this ap	s) of applicant's other application corresponds or compares to the blication as follows:
Computer	r Readable Form	"Sequence Identifier
	olications)	(this application
aj re be	oplication of the applicant on eadable form in lieu of filing a	of a new application is to be identical with the computer readable form of anothe. File in the Office, reference may be made to the other application and compute uplicate computer readable form in the new application. The new application shall g such reference to the other application and computer readable form, both of which 7 C.F.R. 1.821(e).
<b>E.</b> [		e content of each "Sequence Listing" submitted and each compute ame, as required in 37 C.F.R. 1.821(f).
		ent is not made by a person registered to practice before the Office rified as required in 37 C.F.R. 1.821(b).
F. [	-	ssion is made in fulfilling the requirement under 37 C.F.R. 1.821(g) submission includes no new matter.
		ent is not made by a person registered to practice before the Office rified, as required in 37 C.F.R. 1.821(g).

# STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [X] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

#### **STATUS**

5.	Applicant is  [ ] a small entity:	

#### **EXTENSION OF TERM**

6.

NOTE: 37 C.F.R. § 1.704(b)"... an applicant shall be deemed to have failed to engage in reasonable efforts to conclude processing or examination of an application for the cumulative total of any periods of time in excess of three months that are taken to reply to any notice or action by the Office making any rejection, objection, argument, or other request, measuring such three-month period from the date the notice or action was mailed or given to the applicant, in which case the period of adjustment set forth in § 1.703 shall be reduced by the number of days, if any, beginning on the day after the date that is three months after the date of mailing or transmission of the Office communication notifying the applicant of the rejection, objection, argument, or other request and ending on the date the reply was filed. The period, or shortened statutory period, for reply that is set in the Office action or notice has no effect on the three-month period set forth in this paragraph."

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b) as applicable)

(a) [X] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity		ee for nall entity
[X]	one month	\$110.00 \$420.00	\$ \$	55.00 210.00
	three months four months	\$950.00 \$1,480.00	\$ \$	475.00 740.00

Fee \$ 110

If an additional extension of time is required, please consider this a petition therefor.

(Submission-Nucleotide and/or Amino Acid Sequence—page 4 of 6) 9-37

## (check and complete the next item, if applicable)

			[ ] An extension for months has already been secured, and the fee paid therefore of \$ is deducted from the total fee due for the total months of extension now requested.
			Extension fee due with this request \$
			OR
	(b)	[]	Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.
			FEE PAYMENT
8.	[ X	]	Attached is a check in the sum of \$ 110
	[]		arge Account No the sum of \$  duplicate of this transmittal is attached.
			FEE DEFICIENCY
9. <i>NOT</i>	TE:	the before to ap	nere is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover additional time consumed in making up the original deficiency. If the maximum, six-month period has expired ore the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization harge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order pply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency and be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.
10.	[X]		If any additional extension and/or fee is required, charge Account No. 12-0425.

(type or print name of person signing statement) Signature June 17, 2004 Date P.O. Address of Signatory c/o Ladas & Parry LLP 26 West 61st Street New York, N.Y. 10023 ] Inventor Assignee of complete interest (If applicable) ] Person authorized to sign on behalf of assignee Tel. No.: (212) 708-1890 Practitioner of record [ ] Filed under Rule 34(a) Reg. No. 30,086 [ ] Registration No. \_\_\_ [ ] Other (specify identity of person signing) (complete the following, if applicable) (type name of assignee) Address of assignee Title of person authorized to sign on behalf of assignee A "STATEMENT UNDER 37 C.F.R. 3.73(b)" is attached. Assignment recorded in PTO on \_\_\_\_ Reel \_\_\_\_ Frame \_\_\_\_ SIGNATURE OF PRACTITIONER Reg. No. (type or print name of practitioner) Tel. No.: ( P.O. Address

Customer No.:

SIGNATURE(s)

c/o Ladas & Parry LLP 26 West 61st Street New York, N.Y. 10023

(Submission-Nucleotide and/or Amino Acid Sequence—page 6 of 6) 9-37